Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12765773 | 0.79 | ALDH1A1 (0.37) | ALDH1A1SMN1; SMN2EPHX2 | |
| SCHEMBL232917 | 0.79 | EPHX2 (0.47) | ALDH1A1SMN1; SMN2EPHX2 | |
| SCHEMBL12765514 | 0.76 | ALDH1A1 (0.31) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL12837943 | 0.74 | ALDH1A1 (0.32) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL192524 | 0.72 | GRIN2D (0.44) | SMN1; SMN2EPHX2 | |
| SCHEMBL12765518 | 0.72 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL12765761 | 0.72 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL13977492 | 0.72 | EPHX2 (0.42) | EPHX2 | |
| SCHEMBL13968178 | 0.72 | GRIN2D (0.57) | SMN1; SMN2EPHX2 | |
| SCHEMBL12765501 | 0.71 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065762-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | INFLUMEDIX, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110065762-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | INFLUMEDIX, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065762-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | MAVS, SLC30A5, HAVCR2 | ALDH1A1 3877/4885SMN1; SMN2 2955/4885EPHX2 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.